CGON: Cretostimogene advances toward broad NMIBC use with strong data, scalable manufacturing, and launch prep
Recent data indicates that cretostimogene combined with gemcitabine shows increased efficacy and strong safety for BCG-exposed NMIBC patients, supporting a planned Phase III trial. Significant progress in manufacturing and regulatory processes suggests a Biologics License Application (BLA) filing by year-end, with preparedness for product launch and widespread clinical integration already in motion. This information is based on CG Oncology, Inc.'s presentation at the RBC Capital Markets Global Healthcare Conference 2026.
TimesSquare Capital Management LLC Decreases Stock Holdings in CG Oncology, Inc. $CGON
TimesSquare Capital Management LLC reduced its stake in CG Oncology (NASDAQ:CGON) by 15.4% in the fourth quarter, selling 77,507 shares and holding 426,019 shares valued at $17.7 million. Despite missing quarterly earnings estimates with a loss of $0.71 per share, CG Oncology's revenue of $1.08 million surpassed expectations. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $81.73 for the company.
Wolfe Research initiates coverage of CG Oncology (CGON) with peer perform recommendation
Wolfe Research has initiated coverage of CG Oncology (CGON) with a peer perform recommendation. This signifies a neutral outlook on the company's stock performance relative to its industry peers.
CG Oncology stock initiated at Peerperform by Wolfe Research
Wolfe Research initiated coverage on CG Oncology Inc. (NASDAQ:CGON) with a Peerperform rating, acknowledging the stock's significant rise but noting it appears slightly overvalued. The firm expects approval for CG Oncology's creto product in high-risk bladder cancer but anticipates a slow initial launch due to market competition and logistical challenges. Despite these concerns, Wall Street analysts maintain a bullish outlook with price targets suggesting substantial upside.
CG Oncology Initiated at Peer Perform by Wolfe Research
Wolfe Research has initiated coverage of CG Oncology with a "Peer Perform" rating. The article also briefly mentions Unity Software's fourth-quarter financial results, noting a 35% year-over-year revenue increase to $609 million, exceeding estimates, despite a quarterly loss of 66 cents per share.
CGON Initiated Coverage by Wolfe Research -- Rating: Peer Perfor
Wolfe Research has initiated coverage on CG Oncology (CGON) with a 'Peer Perform' rating, indicating expectations for the company to perform in line with its biotechnology peers. CGON, a late-stage clinical biopharmaceutical company focused on bladder cancer, has a market capitalization of $5.55 billion but shows significant weaknesses in profitability with a low GF Score™ of 14/100. Insider selling of $1.3 million over the past three months may also be a point of concern for investors.
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) and CG Oncology have announced the recipients of their second annual NMIBC Research Fellowship: Patrick Hensley, MD, and Daniel Joyce, MD, MS, each receiving a grant up to $50,000 for their work on non-muscle invasive bladder cancer. The fellowship supports clinical cancer research investigators committed to improving NMIBC understanding and treatment. Last year's awardees also presented their research at the SUO 2026 Annual Meeting.
Bladder cancer grants back AI biomarker, price transparency research
CG Oncology and the SUO-CTC have announced the recipients of their second annual NMIBC Research Fellowship, awarding grants of up to $50,000 to Dr. Patrick Hensley and Dr. Daniel Joyce. Their projects focus on developing AI-powered prognostic biomarkers and individualized price transparency for patients with BCG-unresponsive non-muscle invasive bladder cancer. The program aims to advance understanding and treatment in the field, building on previous successful research presentations.
CG Oncology Price Target Maintained With a $100.00/Share by HC Wainwright & Co.
HC Wainwright & Co. has maintained its price target for CG Oncology at $100.00 per share. The article also briefly mentions Unity Software's fourth-quarter financial results, including a 35% year-over-year revenue increase to $609 million, surpassing estimates, and a quarterly loss of 66 cents per share.
CGON Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100
HC Wainwright & Co. has reiterated its "Buy" rating for CGON, maintaining a price target of $100. This news was published on GuruFocus.com. The information provided is for general knowledge and does not constitute investment advice.
Assessing CG Oncology (CGON) Valuation After Strong Phase 2 CORE 008 Cohort CX Trial Data
CG Oncology (CGON) recently released strong Phase 2 CORE-008 Cohort CX data for its bladder cancer treatment, leading to investor interest despite recent short-term share price weakness. The company is valued at US$5.9 billion, and while its price-to-book ratio of 5.4x is considered good value against some peers, it is expensive compared to the broader US biotech industry average. A discounted cash flow model suggests the stock could be significantly undervalued, trading about 81% below its estimated fair value.
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $108
LifeSci Capital has reiterated its Buy rating for CG Oncology (CGON.US) and maintained its target price at $108. This indicates a continued positive outlook from the firm regarding the company's stock performance and valuation.
Will Phase 2 CORE-008 Bladder Cancer Data and Wider Losses Change CG Oncology's (CGON) Narrative
CG Oncology (CGON) reported increased revenue and widened net losses in Q1 2026, ahead of presenting initial Phase 2 CORE-008 data for its bladder cancer treatment at AUA 2026. While the upcoming data reinforces its scientific position, it's considered an incremental sentiment driver rather than a primary stock mover, with ongoing cash burn and future funding needs remaining key investor concerns. The stock's recent share price weakness and significant fair value estimate discrepancies highlight divergent market views.
CG Oncology Reports 'Encouraging' Data From Study of Intravesical Combination Therapy to Treat Bladder Cancer
CG Oncology announced "encouraging" interim data from a Phase 2 study of its intravesical combination therapy, cretostimogene grenadenorepvec with nivolumab, for high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The data, presented at the American Urological Association Annual Meeting, showed a 75% complete response rate and a favorable safety profile, with responses observed across all patient subgroups. This positive outcome supports the potential of this novel therapeutic approach for bladder cancer.
Will Phase 2 CORE-008 Bladder Cancer Data and Wider Losses Change CG Oncology's (CGON) Narrative
CG Oncology (CGON) reported increased revenue but also widened net losses in Q1 2026. The company is set to release initial Phase 2 CORE-008 bladder cancer data at AUA 2026, which is expected to reinforce its scientific positioning rather than significantly alter its commercial outlook. Despite recent stock weakness, the ongoing cash burn and future funding needs remain critical factors for investors to consider.
T. Rowe Price (CGON) reports 6.72M shares, 8.0% stake disclosed
T. Rowe Price Investment Management, Inc. has disclosed an 8.0% stake in CG Oncology Inc. (CGON), amounting to 6,720,389 shares of Common Stock as of March 31, 2026. The filing, a Schedule 13G, indicates a passive investment and states that T. Rowe Price denies beneficial ownership of these securities. It also details that the firm holds sole voting power over 6,459,822 shares and sole dispositive power over all 6,720,389 shares.
RTW Investments Takes Shared 8.3% Stake in CG Oncology (CGON)
RTW Investments, LP and Roderick Wong have reported a shared beneficial ownership of 8.3% in CG Oncology (CGON), totaling 6,984,808 shares of Common Stock. This stake is based on 84,435,200 shares outstanding as of February 25, 2026. The Schedule 13G filing indicates shared voting and dispositive power, with the RTW Funds holding the right to dividends or sale proceeds.
Bladder cancer trial sees up to 92.3% response with new drug combo
CG Oncology announced positive Phase 2 results from its CORE‑008 Cohort CX trial, evaluating an intravesical combination therapy for high‑risk non‑muscle invasive bladder cancer. The study showed high-grade event-free survival rates of up to 96.0% at 3 months and 89.5% at 6 months, with complete response rates reaching 92.3% in efficacy-evaluable CIS-containing patients. The treatment, combining cretostimogene grenadenorepvec with gemcitabine, demonstrated a favorable safety profile with no severe treatment-related adverse events.
CG Oncology stock hits all-time high at 73.61 USD
CG Oncology Inc. (CGON) stock recently achieved an all-time high of $73.61, marking a 201.78% increase over the past year. Despite being considered overvalued by InvestingPro analysis, analysts maintain a bullish outlook with price targets ranging from $77 to $108. Recent positive developments include increased price targets from RBC Capital, UBS, BofA Securities, and Truist Securities, as well as the appointment of Jim DeTore as CFO.
CG Oncology stock hits all-time high at 73.61 USD By Investing.com
CG Oncology's stock reached an all-time high of $73.61, reflecting a remarkable 201.78% surge over the past year and a market capitalization of $6.36 billion. Despite being considered overvalued by InvestingPro, analysts maintain bullish price targets, supported by positive trial data, strategic appointments, and ongoing research into bladder cancer treatments.
Number of shareholders of CG Oncology, Inc. – NASDAQ:CGON
This page provides information on the number of shareholders for CG Oncology, Inc. (NASDAQ: CGON). It is a financial data page from TradingView, offering an overview of the company's financial metrics and market data.
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings
Following its Q1 earnings report, CG Oncology saw analysts raise their price targets despite missing earnings per share estimates but beating revenue expectations. The company confirmed it is on track to finalize its BLA submission in Q4 2026. Shares of CG Oncology rose 0.2% after the announcement.
CG Oncology, Inc. to unveil new data on CORE-008 Cohort CX for bladder cancer
CG Oncology, Inc. will present initial results from its CORE-008 Cohort CX study in bladder cancer at the upcoming American Urological Association Annual Meeting. This presentation is part of the company's continuous efforts to advance bladder cancer treatment and research. CG Oncology has also recently addressed bladder cancer recurrence risks and reported its Q1 2026 financial results, emphasizing ongoing research and development in this field.
CG Oncology brings first bladder cancer combo data to AUA 2026
CG Oncology (NASDAQ: CGON) will present the first results from its CORE-008 Cohort CX Phase 2 trial for high-risk non-muscle invasive bladder cancer (NMIBC) at the AUA 2026 Annual Meeting. The company will also highlight research from its NMIBC Research Fellowship and exhibit its clinical development program. This marks a significant step for CG Oncology in advancing therapies for bladder cancer.
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
CG Oncology will participate in the American Urological Association (AUA) 2026 Annual Meeting, where it will present the first results from its CORE-008 Cohort CX Phase 2 Trial for high-risk non-muscle invasive bladder cancer (NMIBC). The company will also host presentations from grant recipients of the annual CG-SUO-CTC NMIBC Research Fellowship, highlighting its commitment to advancing bladder cancer treatment. This participation reinforces CG Oncology's dedication to developing innovative therapies for NMIBC.
CG Oncology's BLA Completion Target for Creto in Q4 to Comfort Investors, RBC Says
RBC Capital Markets believes that CG Oncology's new target of completing its Biologics License Application (BLA) for cretostimogene in bladder cancer by Q4 2026 will reassure investors. This updated timeline provides more clarity, reducing uncertainty and potentially mitigating concerns about the approval process for the oncolytic virus therapy.
CG Oncology (CGON) Deep LTM Losses Test Bullish Late Stage Pipeline Narratives
CG Oncology (CGON) reported deep losses in FY 2025, with LTM net losses of US$161 million against only US$4.0 million in revenue, highlighting its development-stage status. Despite these losses and a high P/B ratio of 8.1x, bullish investors point to a growing late-stage pipeline, with products in Phase III increasing from two to three, and analyst forecasts for significant future growth and profitability within three years. The article discusses the tension between current financial performance driven by pipeline investment and future growth expectations, suggesting a focus on long-term trends and potential risks associated with valuation and financing needs.
CG Oncology (CGON) Valuation Update As Revenue Growth Meets Wider Quarterly Loss
CG Oncology (CGON) reported Q1 revenue of US$1.08 million and a net loss of US$60.2 million, leading to a re-evaluation of its stock. Despite increased losses, the company has seen significant share price momentum. Its price-to-book ratio suggests the market is placing a substantial premium on its bladder cancer pipeline, though a Discounted Cash Flow model indicates the stock may be undervalued.
CG Oncology says $1.1B cash can fund bladder cancer push through 2029
CG Oncology reported Q1 2026 financial results, highlighting a strong cash position of $1.1 billion, which is projected to fund operations through 2029. The company also announced expected completion of its Biologics License Application (BLA) for HR BCG-unresponsive NMIBC in Q4 2026 and provided timelines for key clinical trial data readouts. Despite an increased net loss and higher R&D and G&A expenses, the market reacted positively to the extended financial runway and progress in its bladder cancer programs.
CG Oncology (NASDAQ:CGON) Announces Quarterly Earnings Results
CG Oncology (NASDAQ:CGON) recently announced its quarterly earnings, reporting an EPS of ($0.71), missing analyst expectations of ($0.58). Despite the EPS miss, the company's revenue of $1.08 million surpassed the anticipated $0.45 million. The stock saw a 0.6% increase in midday trading and maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $79.55.
CG Oncology (CGON) Valuation Update As Revenue Growth Meets Wider Quarterly Loss
CG Oncology (CGON) reported Q1 revenue of US$1.08 million and a net loss of US$60.2 million. While the company's P/B ratio of 8.1x suggests it is overvalued compared to the industry average, a Discounted Cash Flow (DCF) model indicates a significant discount to its estimated future cash flow value, pointing to potential undervaluation. Investors are currently weighing rapid share price momentum against wider losses and the success of its late-stage bladder cancer asset.
CG Oncology, Inc. (CGON) reports Q1 loss, tops revenue estimates
CG Oncology, Inc. (CGON) announced a first-quarter loss that was wider than anticipated but reported revenues exceeding analysts' expectations. The company's net loss per share was $0.78, while revenue reached $1.6 million against an expected $1.09 million. CG Oncology's stock saw a slight increase in premarket trading.
CG Oncology (NASDAQ: CGON) posts Q1 2026 loss but builds $1.1B cash runway
CG Oncology reported a net loss of $60.2 million for Q1 2026, widening from the previous year, but significantly increased its cash, cash equivalents, and marketable securities to $1.1 billion. This substantial cash position, bolstered by a $391.4 million at-the-market equity program, is expected to fund operations through 2029. The company also provided updates on its bladder cancer programs, targeting the completion of its first Biologics License Application (BLA) in Q4 2026 and anticipating topline data from its Phase 3 PIVOT-006 trial in the first half of 2026.
CG Oncology, Inc. posts first quarter 2026 financial results and reveals new business developments
CG Oncology, Inc. has announced its financial results for the first quarter ended March 31, 2026, alongside updates on its business operations. The company, which specializes in therapies for non-muscle invasive bladder cancer (NMIBC), provided details on its performance and recent initiatives. CG Oncology continues to focus on addressing the persistent risk of bladder cancer recurrence and is exploring new treatment options to tackle this challenge.
CG Oncology (Nasdaq:CGON) - Stock Analysis
This report provides a comprehensive stock analysis of CG Oncology (Nasdaq:CGON), a late-stage clinical biopharmaceutical company focused on bladder cancer. It highlights the company's valuation, future growth prospects, past performance, and financial health, noting that the stock is currently trading below its estimated fair value with projected annual earnings growth of over 58%. The analysis also details recent news and updates, including clinical trial results for cretostimogene, financial earnings, and changes in corporate leadership, alongside risk factors like shareholder dilution and revenue volatility.
CG Oncology set to report earnings as bladder cancer data looms
CG Oncology Inc. is scheduled to report its first-quarter earnings, with the focus shifting from widening losses to upcoming pivotal bladder cancer data expected in early June. Analysts anticipate a loss of $0.60 per share, and the company's stock is highly rated by analysts due to its lead drug candidate, cretostimogene. Investors are particularly watching progress on the PIVOT-006 trial, the regulatory timeline for its Biologics License Application, and upcoming data presentations at the American Urological Association's annual meeting.
Wall Street analysts think CG Oncology, Inc. (CGON) could surge 29.78%: Read this before placing a bet
This article focuses on CG Oncology, Inc. (CGON) and the significant upside potential of 29.78% that Wall Street analysts see in the stock. Investors are advised to review this information before making any investment decisions.
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS)
The article highlights bullish sentiments from analysts on three healthcare stocks: CG Oncology, Inc. (CGON), Evolus (EOLS), and Nuvation Bio (NUVB). Analysts from JonesTrading, Stifel Nicolaus, and Truist Financial initiated or maintained Buy ratings, citing significant upside potential for each company's stock based on their current price targets. The consensus for all three companies is a Strong Buy rating from analysts.
CG Oncology set to report earnings as bladder cancer data looms
CG Oncology Inc. is preparing to report its first-quarter earnings, with analysts expecting continued losses but a strong focus on upcoming clinical trial data for its lead bladder cancer drug, cretostimogene. Investors are particularly anticipating topline data from the PIVOT-006 trial in early June, alongside updates on regulatory filings and other data presentations at the American Urological Association's annual meeting. Wall Street shows considerable optimism, with all 15 analysts rating the stock a "Buy" and several recent price target upgrades.
CEO Arthur Kuan to speak at Bank of America, RBC health events
CG Oncology (NASDAQ: CGON) announced that CEO Arthur Kuan and President & COO Ambaw Bellete will participate in two investor conferences in May 2026: the Bank of America Health Care Conference and the RBC Capital Markets Global Healthcare Conference. They will present in fireside chats at both events, with live audio webcasts and replays available on the company's Investor Relations website. CG Oncology is a late-stage clinical biopharmaceutical company focused on bladder cancer treatments.
Could Rising Earnings Estimates and a Zacks Upgrade Redefine CG Oncology’s Core Story (CGON)?
CG Oncology (CGON) recently received a Zacks Rank #2 (Buy) upgrade due to rising earnings estimates, indicating increased optimism about its financial prospects. While this upgrade boosts sentiment and reinforces share price strength, the company's investment narrative remains highly dependent on the success of its cretostimogene bladder cancer program moving from clinical trials to a commercial product. Investors are cautioned that despite the positive sentiment, CG Oncology is still a small-revenue, loss-making business facing significant execution and financing risks.
Could Rising Earnings Estimates and a Zacks Upgrade Redefine CG Oncology’s Core Story (CGON)?
CG Oncology, Inc. (CGON) recently received a Zacks Rank #2 (Buy) upgrade due to improved earnings estimates, which has boosted investor sentiment. While positive, the article emphasizes that the company's investment narrative still hinges on the success of its bladder cancer program moving from clinical trials to commercialization, as it remains a revenue-light, loss-making business with significant execution and financing risks. The upgrade heightens expectations for upcoming data readouts and does not fundamentally alter the underlying risk profile.
Could Rising Earnings Estimates and a Zacks Upgrade Redefine CG Oncology’s Core Story (CGON)?
CG Oncology (CGON) recently received a Zacks Rank #2 (Buy) upgrade due to rising earnings estimates, indicating increased optimism about its financial outlook. While this upgrade boosts sentiment and reinforces recent share price strength, the company remains a small-revenue, loss-making business with execution and financing risks. Investors should consider the impact of successful trial outcomes and potential financing challenges on its market valuation.
CG Oncology, Inc. $CGON Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in CG Oncology (NASDAQ:CGON) by 623.8% in Q4, acquiring an additional 32,607 shares to own a total of 37,834 shares valued at approximately $1.57 million. Other institutional investors have also adjusted their positions in the company. CG Oncology reported a Q4 EPS of $(0.51), beating estimates, and analysts currently have a "Moderate Buy" rating with an average target price of $79.55.
282,506 Shares in CG Oncology, Inc. $CGON Acquired by Jennison Associates LLC
Jennison Associates LLC acquired a new position of 282,506 shares in CG Oncology, Inc. (NASDAQ:CGON) during the fourth quarter, valued at approximately $11.73 million, bringing their ownership to 0.35%. This comes as several other institutional investors have also adjusted their holdings, contributing to a total institutional ownership of 26.56%. Analysts currently hold a "Moderate Buy" rating for CGON, with an average target price of $79.55, following the company beating earnings estimates in its last quarterly report.
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $100
H.C. Wainwright has reiterated its Buy rating for CG Oncology (CGON.US) and maintained its price target of $100. This continued positive outlook suggests the firm's confidence in the company's future performance and valuation.
CG Oncology (CGON) Expected to Announce Quarterly Earnings on Thursday
CG Oncology (CGON) is expected to report its Q1 2026 earnings before market open on Thursday, May 7th, with analysts forecasting ($0.58) EPS and $0.453 million in revenue. The company's earnings call is scheduled for May 8th at 12:30 PM ET. Insider transactions show Director James Mulay sold 15,600 shares, reducing his position by 50%, while analysts presently rate the stock a "Moderate Buy" with an average price target of $79.55.
Pictet Asset Management Holding SA Has $56.03 Million Position in CG Oncology, Inc. $CGON
Pictet Asset Management Holding SA has increased its stake in CG Oncology (NASDAQ:CGON) by 2.3%, now holding 1,349,527 shares valued at approximately $56.03 million. Institutional investors collectively own about 26.56% of the company. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $79.55, reflecting general bullish sentiment despite some mixed reviews.
Why CG Oncology, Inc. Shares Are Sliding Today
CG Oncology, Inc. shares are declining despite the company accelerating the development of its lead bladder cancer therapy, cretostimogene grenadenorepvec, with Phase 3 data expected nearly a year earlier than planned. Analysts have responded positively with higher price targets, suggesting the stock's drop may be due to profit-taking or investor reevaluation of risks associated with the condensed timeline. The market is currently weighing the potential benefits of earlier trial results against inherent uncertainties in late-stage oncology studies.
[ARS] CG Oncology, Inc. SEC Filing
This article announces an ARS SEC filing by CG Oncology, Inc. (CGON) on April 24, 2026, accessible as a PDF document. The filing has a low impact and neutral sentiment. The company's overview includes its market cap, float, industry, and recent news and SEC filings.
